| Bioactivity | Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis[1]. |
| Invitro | Aldometanib (0-1000 nM; 2 h) activates AMPK by preventing aldolase from binding to FBP to engender a pseudo-starvation signal[1]. Western Blot Analysis[1] Cell Line: |
| In Vivo | Aldometanib (oral; 0-10 mpk) reduces blood glucose in lean mice[1].Aldometanib (oral; 2-10 mpk; twice daily; for a week) reduces blood glucose and alleviates fatty liver in obese hyperglycaemic mice[1].Aldometanib alleviates fatty liver and nonalcoholic steatohepatitis[1].Aldometanib (oral; 2mpk; twice-daily; for a month) alleviates liver fibrosis in NASH mice[1].Aldometanib (oral; 0-50 μM; 0-50 days) extends lifespan in C. elegans via the lysosomal pathway[1]. Animal Model: |
| Name | Aldometanib |
| Formula | C27H43Cl2IN2 |
| Molar Mass | 593.45 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| Reference | [1]. Chen-Song Zhang, et al. The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK. Nat Metab. 2022 Oct 10. |